CURI
CuriosityStream Inc.
CURI has the edge over VZ overall, supported by stronger fundamentals and stronger modeled upside.
VZ
Verizon Communications Inc.
VZ has lower modeled downside risk, despite its lower overall score.
CURI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
CURI's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
VZ Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Under pressure |
VZ's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
CURI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $2.86 | — |
| Current | 20x | $2.86 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
CURI has the edge over VZ in the historical PE scenario, which offers more potential upside but is not a forecast.
VZ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.3x | $32.43 | -30% |
| Forward | 9x | $46.55 | — |
| Fair | 11x | $43.63 | -6.3% |
| Current | 12x | $46.55 | — |
| Expensive | 14x | $56.75 | +22% |
Historical ranges are pointers, not guarantees.
VZ's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 9.0x next year's earnings, in its cheap range.
CURI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
CURI has the edge over VZ on the outlook, with more favorable revenue expectations.
VZ Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect VZ's earnings to grow and its profitability to improve, with its revenue holding steady.
CURI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.24 | +75% |
| Q3 2026 | $0.14 | +$0.23 |
| Q2 2026 | $0.00 | +$0.09 |
| Q1 2026 | -$0.14 | $0.00 |
| Q4 2025 | -$0.11 | +$0.13 |
| Q3 2025 | -$0.09 | +$0.18 |
| Q2 2025 | -$0.09 | +$0.62 |
| Q1 2025 | -$0.14 | +$0.72 |
| Q4 2024 | -$0.24 | +$0.68 |
CURI has the edge over VZ on earnings, with more consistent year-over-year improvement.
VZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.19 | +32% |
| Q3 2026 | $3.93 | -16% |
| Q2 2026 | $3.85 | -10% |
| Q1 2026 | $4.11 | -2.1% |
| Q4 2025 | $4.06 | -1.9% |
| Q3 2025 | $4.68 | +103% |
| Q2 2025 | $4.29 | +61% |
| Q1 2025 | $4.20 | +57% |
| Q4 2024 | $4.14 | +51% |
VZ's earnings per share have fallen from their peak: $3.93 over the past year, against $5.34 in late 2021.
CURI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +13% |
| Q2 2026 | $23.2M | +22% |
| Q1 2026 | $15.2M | +0.5% |
| Q4 2025 | $19.2M | +36% |
| Q3 2025 | $18.4M | +46% |
| Q2 2025 | $19M | +53% |
| Q1 2025 | $15.1M | +26% |
| Q4 2024 | $14.1M | -4.3% |
CURI has the edge over VZ on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +42 points |
| Q2 2026 | 39% | +37 points |
| Q1 2026 | -10% | -11 points |
| Q4 2025 | -18% | +9.9 points |
| Q3 2025 | -24% | +1.3 points |
| Q2 2025 | 2.5% | +23 points |
| Q1 2025 | 0.5% | +31 points |
| Q4 2024 | -27% | +4.8 points |
CURI's operating margin was 18% last quarter, up 42 points from the same quarter a year ago, near the top of its range since 2019.
VZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $34.3B | +1.5% |
| Q2 2026 | $34.3B | -0.7% |
| Q1 2026 | $34.4B | +2.9% |
| Q4 2025 | $36.4B | +2% |
| Q3 2025 | $33.8B | +1.5% |
| Q2 2025 | $34.5B | +5.2% |
| Q1 2025 | $33.5B | +1.5% |
| Q4 2024 | $35.7B | +1.6% |
VZ's revenue has held roughly level: $34.3B last quarter, up 1.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 25% | +1.3 points |
| Q2 2026 | 21% | -2.7 points |
| Q1 2026 | 24% | +0.1 points |
| Q4 2025 | 14% | -7.1 points |
| Q3 2025 | 24% | +6.2 points |
| Q2 2025 | 24% | -0.2 points |
| Q1 2025 | 24% | +1 points |
| Q4 2024 | 21% | +19 points |
VZ has the edge over CURI on profitability, with a higher operating margin.
CURI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.4M | +0.5% |
| Q2 2026 | -$4.2M | -249% |
| Q1 2026 | $1.2M | -34% |
| Q4 2025 | $3.9M | +30% |
| Q3 2025 | $4.4M | +94% |
| Q2 2025 | $2.8M | +27% |
| Q1 2025 | $1.8M | +177% |
| Q4 2024 | $3M | +$5.6M |
CURI has burned cash in most quarters: $5M over the past year, down 55% from the year before.
VZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.5B | +2.2% |
| Q2 2026 | $10.4B | +16% |
| Q1 2026 | $8B | +2.6% |
| Q4 2025 | $9.1B | -13% |
| Q3 2025 | $11.3B | +14% |
| Q2 2025 | $9B | -5.4% |
| Q1 2025 | $7.8B | +9.9% |
| Q4 2024 | $10.4B | +20% |
VZ's free cash flow has been positive every quarter for seven years: $39B over the past year, up 1.5% from the year before.
CURI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -164K shares |
| 1 year | +4.3% | +2.5M shares |
| 3 years | +14% | +7.4M shares |
| 5 years | +26% | +12.4M shares |
| Available history | +264% | +43.9M shares |
CURI has 60M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $560,000 |
| Q1 2026 | $311,000 |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $33,000 |
| Q3 2024 | $192,000 |
| Q4 2020 | — |
CURI spent $871,000 buying back its own shares over the past year.
VZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -10M shares |
| 1 year | -1.7% | -72M shares |
| 3 years | -1.3% | -55M shares |
| 5 years | +0.4% | +17M shares |
| Available history | +0.5% | +21M shares |
VZ has the edge over CURI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | $1B |
| Q1 2026 | $2.5B |
CURI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
CURI has the edge over VZ on leverage, with a lower net debt burden relative to earnings.
VZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.3x | Elevated |
| Q2 2026 | 3.4x | Elevated |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 2.9x | Moderate |
| Q3 2025 | 2.8x | Moderate |
| Q2 2025 | 3.0x | Moderate |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 3.0x | Elevated |
VZ's net debt is about 3.3 years of its operating earnings (EBITDA), up from 2.8 years a year ago.
CURI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 14.3 | Oversold |
CURI's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
VZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 44.6 | Neutral |
VZ's weekly RSI is 51 (neutral) and its Stochastic is 45 (neutral).
CURI PE vs Communication Services Sector
VZ PE vs Communication Services Sector
| Metric | VZ | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 16x | 28% below |
| PE % | 58 | 26 | 32 pts above |
VZ is trading at 12x earnings, a 28% discount to the Communication Services sector's median of 16x.
CURI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.78 | 2.9% above |
| 20 week MA | $2.75 | 4% above |
| 50 week MA | $3.07 | 6.8% below |
| 100 week MA | $3.49 | 18% below |
| 200 week MA | $2.31 | 24% above |
CURI's trend is mixed: it's above three of its five weekly moving averages, and 24% above its 200-week average.
VZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $45.1 | 3.1% above |
| 20 week MA | $46.3 | 0.5% above |
| 50 week MA | $46.1 | 1.1% above |
| 100 week MA | $44.2 | 5.4% above |
| 200 week MA | $41.4 | 12% above |
VZ has the edge over CURI on trend strength, trading above more of its moving averages.
CURI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.90 | $13.8 | +39% |
| 2021 | $13.8 | $6.44 | -53% |
| 2022 | $6.44 | $1.17 | -82% |
| 2023 | $1.17 | $0.54 | -54% |
| 2024 | $0.54 | $1.58 | +193% |
| 2025 | $1.58 | $3.83 | +142% |
| 2026 YTD | $3.83 | $2.86 | -25% |
CURI's yearly returns have swung widely, from +193% in 2024 to −82% in 2022. It's down 25% so far in 2026.
VZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.5 | $58.8 | -4.4% |
| 2021 | $58.8 | $52.7 | -10% |
| 2022 | $52.7 | $38.4 | -27% |
| 2023 | $38.4 | $37.7 | -1.8% |
| 2024 | $37.7 | $39.9 | +5.9% |
| 2025 | $39.9 | $40.5 | +1.4% |
| 2026 YTD | $40.5 | $46.6 | +15% |
VZ has the edge over CURI on returns for 2026, with the stronger performance.